Differential effects of levodopa on dopaminergic function in early and advanced parkinson's disease

Annals of Neurology

Volumn 41, Issue 3, 1997, Pages 334-340

  Torstenson, Richard ^a   Harrvig, Per ^a,c   Långström, Bengt ^a,c   Westerberg, Göran ^a,c   Tedroff, Joakim ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CARBIDOPA; CARBON 11; DECARBOXYLASE INHIBITOR; LEVODOPA; PRAMIPEXOLE; SELEGILINE;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE DURATION; DOPAMINERGIC SYSTEM; DRUG UPTAKE; FEMALE; HUMAN; IMAGE RECONSTRUCTION; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BRAIN; DOPAMINE; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031056638     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410410308     Document Type: Article

References (42)

1. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1:292-296
2. 11C]raclopride displacement and PET. Neurology 1996;46:1430-1436
3. 11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response. Acta Neurol Scand 1992;85:95-102
4. Wolf ME, Roth RH. Dopamine autoreceptors. In: Creese I, Fraser CM, eds. Receptor biochemistry methodology: dopamine receptors. New York: Alan R. Liss, 1987:45-96
5. Opacka-Juffry J, Brooks DJ. L-Dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles. Mov Disord 1995;10:241-249
6. Misu Y, Goshima Y. Is L-DOPA an endogenous neurotransmitter? Trends Pharmacol Sci 1993;14:119-123
7. Tedroff J, Torstenson R, Hartvig P, et al. L-DOPA modulates striatal dopaminergic function in vivo. Evidence from PET investigations in non human primates. Synapse 1997;25:56-61
8. Santiago M, Westerink BHC, Rollema H. Responsiveness of striatal dopamine release in awake animal after chronic 1-methyl-4-phenylpyridinium ion-induced lesions of the substantia nigra. J Neurochem 1991;56:1336-1342
9. Hefti F, Enz A, Melamed E. Partial lesions of the nigrostriatal pathway in the rat: acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology 1985;24:19-23
10. Richard MG, Bennet JP. Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism. Exp Neurol 1994;129:57-63
11. Bergström M, Hartvig P, Nava C, et al. Effects of cabergoline on striatal dopamine receptor binding and dopamine synthesis - in vivo study in monkey with positron emission tomography. The meeting of European Neuroscience, Amsterdam, The Netherlands, 1995, p 24 (Abstract)
12. Hartvig P, Tedroff J, Lindner KJ, et al. Positron emission tomographic studies on aromatic L-amino acid decarboxylase activity in vivo for L-DOPA and 5-hydroxy-L-tryptophan in the monkey brain. J Neural Transm 1993;94:127-135
13. 11]DOPA disposition in the monkey brain. Brain Res 1996;713:92-98
14. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32:S125-S127
15. Hoehn MW, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology (Minneap) 1967;17:427-445
16. Tedroff J, Hartvig P, Bjurling P, et al. Central action of benerazide after COMT inhibition demonstrated in vivo by PET. J Neural Transm 1991;85:11-17
17. 11C-labelled L-tyrosine, L-DOPA, L-tryptophan and 5-hydroxy-L-tryptophan. Acta Chem Scand 1990;44:178-182
18. Holte S, Eriksson L, Dahlbom M. A preliminary evaluation of Scanditronix PC 2048-15B scanner. Eur J Nucl Med 1989;15: 719-721
19. Bergström M, Litton J, Eriksson L, et al. Determination of object contour from projections for attenuation correction in cranial positron emission tomography. J Comput Assist Tomogr 1982;6:365-372
20. Andersson J. A rapid and accurate method to realign PET scans utilizing image edge information. J Nucl Med 1995;36:657-669
21. Aquilonius SM, Eckernäs SÅ. A colour atlas of the human brain. Stockholm, Sweden: Esselte Studium, 1980
22. 11C]-3,4-dihydroxyphenylalanine(DOPA) in the primate by positron emission tomography. Acta Neurol Scand 1992;85:166-173
23. Carson RE, Huang SC, Green MV. Weighted integration method for local cerebral blood flow measurements with positron emission tomography. J Cereb Blood Flow Metab 1986;6:245-258
24. 11C]-L-DOPA in humans studied by positron emission tomography. J Neural Transm 1991;87:15-22
25. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301
26. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20:415-455
27. Nyberg P, Nordberg A, Wester P, Winblad B. Dopaminergic deficiency is more pronounced in putamen than in nucleus caudatus in Parkinson's disease. Neurochem Pathol 1983;1:193-202
28. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880
29. Hadjiconstantinou M, Wemlinger TA, Sylvia CP, et al. Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J Neurochem 1993;60: 2175-2181
30. Zhu MY, Juorio AV, Paterson A, Boulton AA. Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors. Eur J Pharmacol 1993; 238:157-164
31. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine treated rats. Brain Res 1990;525:36-44
32. Tissari AH, Lillgäls MS. Reduction of dopamine synthesis inhibition by dopamine autoreceptor activation in striatal synaptosomes with in vivo reserpine administration. J Neurochem 1993;61:231-238
33. Seutin V, Verbanck P, Massotte L, Dresse A. Acute amphetamine-induced subsensitivity of A10 dopamine autoreceptors in vitro. Brain Res 1991;558:141-144
34. White FJ, Wang RY. Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronic D-amphetamine treatment. Brain Res 1984;309:283-292
35. Calabresi P, Pisani A, Mercuri NB, Bernardi G. The corticostriatal projections: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci 1996;19:19-24
36. Agid Y. Dopaminergic system in Parkinson's disease. In: Quinn NP, Jenner PD, eds. Disorders of movement: clinical, pharmacological and physiological aspects. London: Academic Press, 1989:85-107
37. Mouradian MM, Juncos JL, Fabbrini G, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanism, part II. Ann Neurol 1988;24:372-378
38. Contin M, Riva R, Martinelli P, et al. Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 1993;43:367-371
39. Bredberg E, Tedroff J, Aquilonius SM, Paalzow L. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. Eur J Clin Pharmacol 1990;39:385-389
40. Sohn YH, Metman V, Bravi D, et al. Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease. Neurology 1994;44:755-757
41. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573
42. Frauenfelder H, Sligar SG, Wolynes PG. The energy landscapes and motions of proteins. Science 1991;254:1598-1603